Updated:
Rallybio
Rallybio is a clinical-stage biotech launched in 2018 by former Alexion R&D chiefs to develop antibodies for rare diseases with no approved therapies.
Rallybio
Rallybio was formed in 2018 by Martin Mackay, the former R&D chief of Alexion, and Steve Uden, a former Alexion neuroscience head, alongside a syndicate of veteran biotech investors. The company structured itself as a publicly traded biotech from the start, completing an NYSE listing in July 2021 (per the firm's SEC filings). Its founding thesis was straightforward: apply the same biomarker-driven, rare-disease development approach that built Alexion into a $39 billion acquisition target, but concentrated inside a leaner, earlier-stage entity. The company's preclinical and clinical portfolio targets hematology, maternal-fetal health, and complement-mediated disorders. Its lead program, RLYB212, is a monoclonal antibody designed to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), a rare and potentially fatal condition with no approved therapy. Rallybio is also developing RLYB116, a subcutaneous inhibitor of complement component C5, and RLYB331, an antibody targeting Matriptase-2 for iron-loading anemias (per the firm's investor presentations, 2024). The geographic focus spans US and European clinical trial sites, with a discovery team based in New Haven, Connecticut. Rallybio raised roughly $80 million in private funding from investors including 5AM Ventures, Canaan Partners, and New Leaf Venture Partners before its public debut, and reported approximately $120 million in cash and equivalents at year-end 2023 (per the firm's 10-K, February 2024). The company has stayed deliberately small, with no disclosed international offices and a headcount concentrated in R&D. In November 2023, Rallybio announced a strategic reprioritization that narrowed its pipeline focus to RLYB212 and its complement programs, and Steve Uden shifted from CEO to a strategic advisor role, with Martin Mackay stepping into the CEO position (per the firm, November 2023). Rallybio's structural differentiator is its status as a rare-disease pure-play that went public pre-revenue with a multi-program portfolio, rather than building around a single lead asset. The firm's executive team and board carry deep relationships with rare-disease patient registries and academic sub-specialists, a sourcing moat that mirrors the early Alexion playbook. Its ability to run concurrent Phase 2 programs across unrelated rare diseases — FNAIT, paroxysmal nocturnal hemoglobinuria, iron-refractory anemias — depends entirely on maintaining capital market access, a governance tension typical for micro-cap biotechs that institutional allocators track closely.
General information
Firm type
Asset Manager
Year founded
2018
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New Haven
Corporate office
New Haven, CT, United States
Principals
Stephen Uden
Chief Executive Officer
Martin Mackay
Co-Founder and Chairman of the Board
Jeffrey Fryer
Chief Financial Officer
Sector focus
Frequently asked questions
What is Rallybio's relationship to Alexion Pharmaceuticals?
Rallybio was co-founded by Martin Mackay and Stephen Uden, both former senior R&D leaders at Alexion. Mackay served as Alexion's global head of R&D, and Uden led neuroscience research. Rallybio applies a similar biomarker-driven, rare-disease development model but operates as a standalone, publicly traded company with no ongoing corporate ties to Alexion or AstraZeneca, which acquired Alexion in 2021.
Who runs investment decisions at Rallybio?
Rallybio is an operating biotechnology company, not an investment firm. It does not manage third-party capital or make fund investments. Capital allocation decisions are made by the executive team led by CEO Martin Mackay and CFO Jeffrey Fryer, overseen by a board of directors that includes representatives from early investors 5AM Ventures and Canaan Partners (per the firm's proxy statements, 2024).
What is Rallybio's lead drug candidate and why does it matter?
RLYB212 is a monoclonal antibody designed to prevent fetal and neonatal alloimmune thrombocytopenia (FNAIT), a condition where maternal antibodies destroy fetal platelets, causing intracranial hemorrhage or death. Currently, there is no approved therapy for FNAIT. Rallybio is conducting a Phase 2 trial, and the program represents the company's most advanced asset (per the firm, 2024).
How does Rallybio finance its operations?
Rallybio went public on the Nasdaq in July 2021, raising approximately $80 million in gross proceeds. Before that, it raised private venture capital from 5AM Ventures, Canaan Partners, and New Leaf Venture Partners. The company relies on periodic public equity offerings to fund clinical development. It reported cash and equivalents of roughly $120 million at the end of 2023 (per SEC filings, February 2024).
Is Rallybio structured as a single-family office?
No. Rallybio is a publicly traded biotechnology corporation listed on the Nasdaq under the ticker RLYB. It is not a family office, does not manage family wealth, and has no connection to any single-family wealth origin. It is a clinical-stage drug development company funded by institutional venture capital and public market investors.
Which diseases does Rallybio explicitly target?
Rallybio focuses exclusively on rare diseases in three areas: hematology (FNAIT and iron-refractory anemia), maternal-fetal health, and complement-mediated disorders. It has publicly stated it does not develop therapies for large primary-care indications or oncology, concentrating instead on diseases with well-understood biology, clear biomarkers, and no approved treatments.
What happened to Rallybio's leadership in late 2023?
In November 2023, Rallybio announced a pipeline reprioritization and a leadership transition. Co-founder Stephen Uden moved from CEO to a strategic advisory role on the board, and co-founder Martin Mackay, previously Chairman, assumed the CEO position. The company also streamlined its operations to focus on three core programs: RLYB212, RLYB116, and RLYB331 (per the firm, November 2023).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: